EUDA Health EUDA

Medical - Care Facilities, Healthcare

$12.78

−4.41%

Market cap: $24.2M
PE: n/m; not a meaningful number
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; not a meaningful number
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: n/m; not a meaningful number

Charts

Financials

Income statement for EUDA, by quarter
Income statement	Q3 FY21	Q4 FY21	Q1 FY22	Q2 FY22	Q1 FY22	Q3 FY22	Q4 FY22	Q2 FY22	Q1 FY23
	n/a	n/a	n/a	n/a	$2.7M	n/a	n/a	n/a	$1.7M−36%
Cost of revenue	n/a	n/a	n/a	n/a	$1.4M	n/a	n/a	n/a	$1.3M−7%
Gross profit	n/a	n/a	n/a	n/a	$1.3M	n/a	n/a	n/a	$403.6K−68%
R&D	n/a	n/a	n/a	n/a	$2.9K	n/a	n/a	n/a	n/a
SG&A	n/a	n/a	n/a	n/a	$1.2M	n/a	n/a	n/a	$2.4M+100%
	−$6.7K	−$528	−$45.6K	−$225.6K	$75.3K	−$481.6K	−$1.2M	−$298.3K	−$2M
Pre-tax income	n/a	n/a	n/a	n/a	$230.8K	n/a	n/a	n/a	−$2.4M
	n/a	n/a	n/a	n/a	$5.8K	n/a	n/a	n/a	$985−83%
Net income	−$6.7K	−$528	−$45.6K	−$224.9K	$222.6K	−$473K	−$1M	$201K	−$2.4M
	n/a	n/a	−$0.40	n/a	$0.40	n/a	n/a	n/a	−$2.40
	n/a	n/a	93.8K	n/a	462.7K	n/a	n/a	n/a	1M+118%

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest EUDA Health's size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
EUDAEUDA Health	$24.2M	n/m	n/a	n/m	n/m	n/m
NEPHNephros	$38.3M	22.1×	28.4×	1.9×	+24%	8.4%
ATNMActinium Pharmaceuticals	$47.8M	4.2×	3.1×	n/m	n/m	n/m
APTAlpha Pro Tech	$56.7M	13.6×	14.8×	0.9×	+6%	6.8%
SPROSpero Therapeutics	$64.6M	10.1×	9.5×	1.4×	−3%	15.7%
LFVNLifevantage	$73.4M	14.7×	19.6×	0.4×	−20%	2.8%
ICCCImmucell	$93.1M	128×	44.0×	3.0×	+8%	2.6%
KEQUKewaunee Scientific	$94.9M	11.9×	13.7×	0.3×	+5%	3.0%
PDEXPro DEX	$199.3M	15.1×	16.6×	2.6×	+16%	17.6%
PLXProtalix BioTherapeutics	$205.5M	11.1×	34.2×	2.5×	+30%	23.5%
NATRNatures Sunshine Products	$213.8M	12.0×	20.6×	0.4×	+7%	3.7%
Peer median	$83.3M	12.8×	18.1×	1.4×	+7%	6.8%